Company intelligence / Profile preview

Psynova Neurotech

Cambridge, United Kingdom

Ownership: Private
Development stage: Other

Overview

Psynova developed a blood-based diagnostic test (VeriPsych) that aids in the diagnosis of schizophrenia using a panel of 51 biomarkers validated across more than 800 blood samples across 5 clinical centers, achieving an average sensitivity and specificity of 85% or greater[3]. The test was commercially released in autumn 2010 and tested by over 30 institutions[3]. VeriPsych was found to help some patients with poor insight and their families accept diagnosis[3].

Therapeutic areas: Psychiatry
Modalities: ProteinBiomarker
Industry: Protein Biomarker Diagnostics

Partnerships

Rules-Based Medicine (Myriad RBM Inc.)RocheUniversity of Cambridge

Beyond the preview

Go deeper on Psynova Neurotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Psynova Neurotech.

Explore the full profile